Fig. 1.

Disease modifying treatment and symptoms reported by people with MS following COVID-19 vaccination. People with MS were vaccinated with either BNT162b2 or AZD1222. The left panel indicates the time from last/current disease modifying treatment (DMT) until first vaccination. The first and second dots delineate the time between last treatment and first vaccination; the last dot indicates the time point of second vaccination. The median time from last DMT administration to first vaccination in pwMS was 4 months (3-5.6, n=62) for ocrelizumab, 22 (18.3-32.7, n=49) for cladribine, 40 (20-46.2, n=14) for alemtuzumab, 0.3 (0.2-0.5, n=14) for natalizumab, and 6 (3.3-6.5, n=3) for other DMT. The right panel describes the symptoms reported following first and second vaccination, stratified by DMT.